Physician profile
Eva A Hurst
NPI 1023220464
$6,102.31
in general payments reported to CMS, 2019-2025
35 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $442 · 2021: $416 · 2022: $663 · 2023: $1,937 · 2024: $1,070 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.60 |
| Education | $181.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $769.53 | 2020-2025 | |
| Lilly USA, LLC | $760.68 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $677.52 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $667.54 | 2020-2025 | Tremfya, Remicade, Simponi |
| Regeneron Healthcare Solutions, INC. | $656.25 | 2020-2025 | Libtayo, Dupixent |
| Amgen INC. | $501.56 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $313.46 | 2020-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $271.60 | 2019-2025 | Winlevi |
| Leo Pharma INC. | $151.64 | 2020-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $146.76 | 2023-2025 | |
| Kerecis Limited | $126.06 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genzyme Corporation | $122.52 | 2021-2024 | |
| Biofrontera INC. | $103.63 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $99.84 | 2023-2024 | Puraply |
| Mayne Pharma Commercial LLC | $92.72 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.22 | 2023-2025 | Jublia, Arazlo, Siliq |
| Genentech USA, INC. | $62.54 | 2020-2024 | Erivedge |
| Revance Therapeutics, INC. | $60.09 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $53.87 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2023 | Spevigo, Cyltezo |
| Organon LLC | $46.38 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $44.58 | 2022-2023 | |
| Almirall LLC | $26.90 | 2020-2025 | Klisyri |
| Allergan, INC. | $26.05 | 2019 | |
| Biowound Solutions, INC. | $24.30 | 2025 | Bio-Connekt |
| Journey Medical Corporation | $20.79 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.65 | 2019 | |
| Dermavant Sciences, INC. | $19.64 | 2024 | Vtama |
| Botanix Sb INC | $19.12 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $16.36 | 2022 | |
| Pfizer INC. | $16.25 | 2022 | |
| Epi Health, LLC | $16.23 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.58 | 2020 | |
| Integra Lifesciences Corporation | $15.09 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Verrica Pharmaceuticals INC. | $13.01 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.